Press Releases

Investor Resources
Contact Us
Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024


September 10, 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders


June 27, 2024

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT


June 25, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis


June 13, 2024

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024


May 14, 2024

Cardiol Therapeutics Announces Year-End 2023 Update on Operations


April 2, 2024

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis


February 21, 2024

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis


February 15, 2024

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market


January 24, 2024

2025 Cardiol Therapeutics. All right reserved.